A previous study reported that a higher rate of patients with DLBCL treated with CD28 costimulatory domain anti‐CD19 CAR‐T cells had CRS than those treated with 4‐1BB costimulation anti‐CD19 CAR‐T cells.56 This evidence concerns the gene CD28 and diffuse large B-cell lymphoma.